These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19215629)

  • 1. Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users.
    Krebs TS; Johansen PØ; Jerome L; Halpern JH
    Psychol Med; 2009 May; 39(5):876-8. PubMed ID: 19215629
    [No Abstract]   [Full Text] [Related]  

  • 2. No evidence of decrease in cognitive function in users of low-dose Ecstasy.
    Krebs TS; Johansen PØ
    Arch Gen Psychiatry; 2008 Feb; 65(2):236; author reply 236-7. PubMed ID: 18250261
    [No Abstract]   [Full Text] [Related]  

  • 3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
    Rogers G; Elston J; Garside R; Roome C; Taylor R; Younger P; Zawada A; Somerville M
    Health Technol Assess; 2009 Jan; 13(6):iii-iv, ix-xii, 1-315. PubMed ID: 19195429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ecstasy, new psychotropic drugs].
    Djezzar S
    Soins Psychiatr; 2009; (262):35-7. PubMed ID: 19579485
    [No Abstract]   [Full Text] [Related]  

  • 6. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.
    Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B
    Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
    Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
    J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The external validity of results derived from ecstasy users recruited using purposive sampling strategies.
    Topp L; Barker B; Degenhardt L
    Drug Alcohol Depend; 2004 Jan; 73(1):33-40. PubMed ID: 14687957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
    Keyes KM; Martins SS; Hasin DS
    Drug Alcohol Depend; 2008 Sep; 97(1-2):139-49. PubMed ID: 18524499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
    Halpern JH; Sherwood AR; Hudson JI; Gruber S; Kozin D; Pope HG
    Addiction; 2011 Apr; 106(4):777-86. PubMed ID: 21205042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.
    Fox HC; Parrott AC; Turner JJ
    J Psychopharmacol; 2001 Dec; 15(4):273-81. PubMed ID: 11769821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
    Daumann J; Till B; Fischermann T; Rezk M; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
    Huxster JK; Pirona A; Morgan MJ
    J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E; Daumann J
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.